
    
      This was an open-label, multicenter extension study that was conducted to evaluate the safety
      and efficacy of etanercept in the treatment of adult subjects with AS who had completed study
      0881A3-311-EU. The study consisted of an open-label treatment period of up to approximately
      96 weeks.
    
  